Icon (ICLR) Stock Price, News & Analysis

Company Overview

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Key Stats

• Today's Range: $175.01 to $181.51
• 50-Day Range: $139.63 to $195.01
• 52-Week Range: $125.10 to $328.35
• Volume: 621,494 shs
• Average Volume: 1.31 million shs
• Market Capitalization: $14.26 billion
• P/E Ratio: 18.17
• Dividend Yield: N/A
• Price Target: $218.38
• Consensus Rating: Moderate Buy

Icon Stock Analysis - MarketRank™

Icon scored higher than 85% of companies evaluated by MarketBeat, and ranked 163rd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Icon has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 8 buy ratings, 6 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Icon has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 14.28%

Earnings Growth

Earnings for Icon are expected to grow by 14.28% in the coming year, from $13.38 to $15.29 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Icon is 18.43, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.34.

Price to Earnings Ratio vs. Sector

The P/E ratio of Icon is 18.43, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.96.

Price to Earnings Growth Ratio

Icon has a PEG Ratio of 2.67. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Icon has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.70% of the float of Icon has been sold short.

Short Interest Ratio / Days to Cover

Icon has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Icon has recently decreased by 5.86%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Icon does not currently pay a dividend.

Dividend Growth

Icon does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.70% of the float of Icon has been sold short.

Short Interest Ratio / Days to Cover

Icon has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Icon has recently decreased by 5.86%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.02

News Sentiment

Icon has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Icon this week, compared to 10 articles on an average week.

Search Interest

8 people have searched for ICLR on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.

MarketBeat Follows

6 people have added Icon to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Icon insiders have not sold or bought any company stock.

Percentage Held by Insiders

44.00% of the stock of Icon is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.61% of the stock of Icon is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ICLR Stock Analysis - Frequently Asked Questions

How have ICLR shares performed this year?

Icon's stock was trading at $209.71 on January 1st, 2025. Since then, ICLR shares have decreased by 14.9% and is now trading at $178.5230.

How were Icon's earnings last quarter?

Icon Plc (NASDAQ:ICLR) issued its quarterly earnings results on Wednesday, July, 23rd. The medical research company reported $3.26 earnings per share for the quarter, beating the consensus estimate of $3.18 by $0.08. The company's quarterly revenue was down 4.8% compared to the same quarter last year.
Read the conference call transcript.

Does Icon have any subsidiaries?

The following companies are subsidiaries of Icon: PRA Health Sciences, MedPass International, MeDiNova Research, MolecularMD, Mapi Group, Clinical Research Management, PMG Research, and others.

Who are Icon's major shareholders?

Top institutional investors of Icon include Artisan Partners Limited Partnership (8.90%), Massachusetts Financial Services Co. MA (4.65%), Invesco Ltd. (3.82%) and Ninety One UK Ltd (3.71%).

How do I buy shares of Icon?

Shares of ICLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Icon own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Icon investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Adobe (ADBE), Novo Nordisk A/S (NVO) and Jabil (JBL).

Company Calendar

• Last Earnings: 7/23/2025
• Today: 8/22/2025
• Next Earnings (Estimated): 10/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:ICLR
• CIK: 1060955
• Web: www.iconplc.com
• Phone: (531) 291-2000
• Fax: 353-1247-6260
• Employees: 41,900
• Year Founded: 1990

Price Target and Rating

• Average Price Target for Icon: $218.38
• High Price Target: $311.00
• Low Price Target: $150.00
• Potential Upside/Downside: +24.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): $9.72
• Trailing P/E Ratio: 18.13
• Forward P/E Ratio: 13.17
• P/E Growth: 2.67
• Net Income: $791.47 million
• Net Margins: 9.82%
• Pretax Margin: 10.11%
• Return on Equity: 10.95%
• Return on Assets: 6.23%

Debt

• Debt-to-Equity Ratio: 0.35
• Current Ratio: 1.29
• Quick Ratio: 1.29

Sales & Book Value

• Annual Sales: $8.28 billion
• Price / Sales: 1.72
• Cash Flow: $19.60 per share
• Price / Cash Flow: 8.99
• Book Value: $118.32 per share
• Price / Book: 1.49

Miscellaneous

• Outstanding Shares: 80,760,000
• Free Float: 45,224,000
• Market Cap: $14.23 billion
• Optionable: Optionable
• Beta: 1.17